Participants were randomized to receive intravenous (IV) Opdivo or placebo at 240 mg every two weeks. They received adjuvant treatment for up to 1 year. Stratification factors included tumor PD-L1 ...

Bristol-Myers Squibb Company (NYSE:BMY) 45th Annual TD Cowen Health Care Conference March 4, 2025 2:30 PM ETCompany ParticipantsAdam Lenkowsky - ...

compared to Opdivo monotherapy after complete resection of stage III-IV melanoma. The primary endpoint of the trial is recurrence-free survival (RFS). Secondary endpoints include overall survival ...

With our sales team out in the field, relaying the benefits of OPDIVO Qvantig, Bristol shares that the early feedback has been positive for the shorter injection time compared to IV nivolumab.

An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.

Roche plans to drive IV to subcu conversion and believe that subcutaneous formulation will be protective of the brand. And recall that we project receiving royalties on TECENTRIQ Hybriza until 2040.

The Phase 3 study enrolled patients whose stage III to IV melanoma was completely removed ... in combination with nivolumab (brand name Opdivo), a different BMS immunotherapy that’s already ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2024 Earnings Call Transcript February 18, 2025 Halozyme Therapeutics, Inc. beats earnings expectations. Reported EPS is $1.26, expectations were $1.17 ...

The US Food and Drug Administration has approved tislelizumab (Tevimbra, BeiGene), in combination with platinum-containing ...

In adjuvant melanoma, Opdivo(R) (nivolumab) remains a standard of care for adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV ...